Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health    CVS

CVS HEALTH (CVS)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

CVS: By the Numbers: Real-World Impact of Rising Drug Costs

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/16/2017 | 01:55pm CET

Release date- 15062017 - CVS Health - Prescription drug prices continue to be a serious concern as rising prices outpace overall health care inflation. In 2015 alone, 16.7 percent of all U.S. health care dollars was spent on prescription drugs.

This rise in costs not only places a heavy burden on patients and payors, it ultimately affects U.S. taxpayers. To understand the real-world impact of rising drug costs on Americans, we conducted a survey of 2,195 registered voters in April 2017.

Voters are Overwhelmingly Concerned

Eighty-eight percent of respondents report being somewhat or very concerned about the high cost of prescription drugs. A higher percentage of women than men report being very concerned about drug prices (60 percent vs. 47 percent, respectively). Voters aged 45-65 are more likely to report concern than their younger counterparts, as are voters who take three or more prescription drugs.

Many Believe Increasing Competition and Accelerating Drug Reviews Can Help

Nearly one in two (47 percent) voters believe that there aren't enough different prescription drugs available to patients to treat their diseases and conditions. Forty-seven percent also believe that there is not enough competition in the pharmaceutical marketplace. Among voters aged 55-64, that number jumps to 60 percent.

There is, however, majority support for quicker market entry of lower-cost alternatives to brand-name drugs. Fifty-eight percent of respondents are supportive of proposals to speed up FDA approval of biosimilar drugs, which are near-identical copies of original biologic products; this means that there are no clinically significant differences in safety and efficacy.

CVS Health is Committed to Making Medications More Accessible and Affordable

We employ industry-leading strategies to encourage more competitive pricing and reduce costs for patients and payors. For example:

CVS Caremark uses industry expertise to negotiate discounts with manufacturers. These are passed on to plan sponsors and can be used to lower premiums or reduce cost-sharing for consumers.

We developed the capability for clients to apply negotiated discounts at the point-of-sale, to reduce a member's out-of-pocket cost for a prescription when they are at the pharmacy counter.

By encouraging the use of lower-cost, clinically equivalent medicines, such as generics and biosimilars, we can help patients achieve the same health outcomes at a more affordable cost.

We also lower costs through the Reduced RxTM program, which helps patients with high out-of-pocket costs afford their medications.

For more information on how CVS Health is working to ensure consumers have access to affordable medicines, visit our Rising Drug Prices information center. And to stay informed about the most talked-about topics in health care, register for content alerts and our bi-weekly health care newsletter.

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH
05:24pAlbertsons to buy rest of Rite Aid as Amazon threat looms
RE
03:10pCVS HEALTH : Fast Company Recognizes CVS Health on 2018 World's Most Innovative ..
PR
02/15CVS HEALTH : Management's Discussion and Analysis of Financial Condition and Res..
AQ
02/14CVS HEALTH : increasing starting pay to $11 an hour
AQ
02/12CVS HEALTH : latest to boost pay, programs thanks to federal tax reform
AQ
02/10CVS HEALTH : Salisbury town center CVS sold for $7.9 million
AQ
02/10CVS HEALTH : CEO Reveals How It Will Benefit From Tax Reform
AQ
02/09CVS HEALTH CORP : Other Events (form 8-K)
AQ
02/09CVS HEALTH : to Raise Starting Wage -- WSJ
DJ
02/08CVS HEALTH : New CVS Health Poll Reveals That A Majority of U.S. Women Are Unawa..
AQ
More news
News from SeekingAlpha
11:06aHealthcare Innovation Or Exacerbating The Crisis? 
02/19Healthcare In Transition 
02/15The MnM Portfolio - Checking In On Portfolio Fundamentals 
02/14ROAD TO FINANCIAL INDEPENDENCE : My January 88-Stock Portfolio Review 
02/14My Dividend Achievers Finally Pass The Index 
Financials ($)
Sales 2018 189 B
EBIT 2018 9 905 M
Net income 2018 5 788 M
Debt 2018 20 395 M
Yield 2018 3,01%
P/E ratio 2018 12,80
P/E ratio 2019 11,75
EV / Sales 2018 0,49x
EV / Sales 2019 0,46x
Capitalization 72 834 M
Chart CVS HEALTH
Duration : Period :
CVS Health Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 88,1 $
Spread / Average Target 23%
EPS Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH-3.74%72 834
WALGREENS BOOTS ALLIANCE-5.69%70 258
EXPRESS SCRIPTS HOLDING CO-0.76%42 608
MCKESSON CORPORATION-4.60%31 375
AMERISOURCEBERGEN4.99%21 835
CARDINAL HEALTH9.91%21 822